Zykadia (ceritinib) / Novartis, BeiGene  >>  Phase 1
Welcome,         Profile    Billing    Logout  

4 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zykadia (ceritinib) / Novartis
NCT03501368: Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma

Active, not recruiting
1
27
US
Ceritinib, ZYKADIA, Trametinib, MEKINIST
H. Lee Moffitt Cancer Center and Research Institute, Novartis Pharmaceuticals
Melanoma, Unresectable Melanoma, Advanced Melanoma
10/22
08/24
NCT02393625: Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer

Active, not recruiting
1
57
Europe, Canada, US, RoW
Ceritinib (LDK378), Nivolumab
Novartis Pharmaceuticals
ALK-positive NSCLC
04/25
04/25
NCT02321501: Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

Active, not recruiting
1
37
US
Ceritinib, LDK 378, LDK378, Zykadia, Everolimus, 42-O-(2-Hydroxy)ethyl Rapamycin, Afinitor, Certican, RAD 001, RAD001, Votubia, Zortress, Laboratory Biomarker Analysis, Pharmacological Study
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
ALK Positive, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, ROS1 Gene Rearrangement, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
12/24
12/24
NCT03611738: Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

Active, not recruiting
1
21
US
Ceritinib, Zykadia®, tyrosine kinase inhibitor, Docetaxel, Taxotere®, intravenous microtubule inhibitor
H. Lee Moffitt Cancer Center and Research Institute
Non-small Cell Lung Cancer, Lung Cancer, Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB, Stage IV Non-small Cell Lung Cancer, EGFR Negative Non-Small Cell Lung Cancer
04/25
04/25

Download Options